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Background: The Yin Yang 1 (YY1) transcription factor has been identified to target a plethora of potential target
genes, which are important for cell proliferation and differentiation. Although the role that YY1 plays in different
human types of cancer has been reported, its biological and mechanistic significance in melanoma has not been
well defined.
Methods: Quantitative RT-PCR analysis was used to determine whether aberrant YY1 and miR-9 expression occurred in
melanoma, compared with benign nevi and normal tissue controls. Furthermore, the transcriptional regulation of YY1
on miR-9 expression was assessed by using quantitative ChIP-PCR assay. Subsequently, the effects of YY1 and miR-9 on
proliferation, cell cycle, migration and invasion of melanoma cells were detected using CCK-8, flow cytometric analysis,
wound healing and transwell invasion assays, respectively. Finally, the post-transcriptional regulation of miR-9 on RYBP
was analyzed using luciferase reporter and immunoblot analysis.
Results: Elevated YY1 levels were observed in patients with melanoma, compared with benign nevi and normal tissue
controls, and the increased YY1 was associated with melanoma metastasis state and tumor stage. Furthermore, YY1
negatively regulated miR-9 transcription. Silencing of YY1 inhibited proliferation, cell cycle progression, migration and
invasion in melanoma cells, while ectopic of miR-9 did the same. Additionally, RYBP was shown to be a direct target of
miR-9 through binding to its 3′ UTR, thus forming a YY1 ~miR-9 ~ RYBP axis.
Conclusions: These results identify a novel YY1 ~miR-9 ~ RYBP axis involved in melanoma tumorigenesis and reinforce
the idea that regulatory circuitries involving miRNAs and TFs are prevalent mechanisms.
Keywords: YY1, Melanoma tumorigenesis, miR-9 ~ RYBP axisIntroduction
Yin Yang 1 (YY1), also known as δ, NF-E1, UCRBP and
CF1, is a ubiquitously distributed transcription factor be-
longing to the GLI-Kruppel class of zinc finger proteins
that is involved in repressing and activating a diverse
number of promoters. Studies have demonstrated the as-
sociation and modulation of YY1 by the adenovirus-
derived E1A, an oncoprotein that induces YY1-mediated
activation of transcription. In the absence of E1A, the
activity of YY1 is reversed, converting to a transcrip-
tional repressor, hence the name Yin Yang 1 [1–3]. Since
YY1 is a general transcription factor involved in approxi-
mately 10 % of the total mammalian genes, the expres-
sion levels of YY1 must be tightly monitored for the* Correspondence: jiaojian@medmail.com.cn
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YY1 protein levels have been shown to affect the clinical
behavior of several cancer types [4–9].
The putative role of YY1 in tumorigenesis has been
supported by its interaction with different molecules.
Cicatiello et al. reported that cyclin D1 gene promoter
activation in estrogen-responsive human breast cancer is
marked by release of the YY1 transcriptional repressor
complex including HDAC-1 [10]. Alternatively, YY1 has
also been shown to activate c-myc promoter in tumor
cells [11, 12]. Moreover, YY1 has been found to be asso-
ciated with the tumor suppressor p53 [13, 14]. Sui et al.
demonstrated that ablation of endogenous YY1 results
in p53 accumulation due to a reduction in p53 ubiquiti-
nation in vivo [15]. Recent study has revealed that YY1
could help Polycomb Group (PcG) protein recruitmenticle distributed under the terms of the Creative Commons Attribution License
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late tumorigenesis [16, 17].
Studies have repeatedly showed that in the majority of
the tumors studied, YY1 transcript levels are significantly
higher than in the relative normal counterparts for each
cancer type analyzed. Varambally et al. showed that YY1
was significantly higher in primary prostate cancers than
in metastatic prostate cancers [18]. YY1 was also overex-
pressed in colon cancer in the absence of gene amplifica-
tion and chromosomal translocation [19]. Accordingly,
elevated YY1 level were consecutively found in ovarian
cancer, breast cancer, cervical cancer, and osteosarcoma
[20]. However, there is limited information available as
to the involvement of YY1 in melanoma.
Melanoma is the deadliest form of skin cancer, charac-
terized by a rapid progression, metastasis to regional
lymph nodes and distant organs as well as a limited effi-
ciency of therapeutics [21–23]. It is readily curable if di-
agnosed at an early stage, however a large percentage of
melanomas arise without association with premalignant
nevi. This leads to ineffective early detection and results
in approximately 10 % of patients presenting with meta-
static disease upon first diagnosis. Although melanoma
is among the most notoriously aggressive and treatment-
resistant of human cancers, recent studies have yielded
the identification of multiple melanoma oncogenes, sev-
eral of which seem to have been successfully targeted
with small molecules. For example, approximately 50 %
of malignant melanomas harbor a BRAF activating mu-
tation, the majority of these being BRAFV600E [24, 25],
which results in constitutive activation of BRAF and in-
creased activation of the MAPK pathway. Based on these
findings, many preclinical studies have investigated the po-
tential therapeutic value of targeting BRAFV600E, and sev-
eral selective BRAF inhibitors have been developed for
clinical applications in melanoma, as PLX4032 (also
known as vemurafenib) [26–28], GSK2118436 (also
known as dabrafenib) [29], and GSK1120212 (also known
as trametinib) [30, 31]. Thus, it is essential to identify add-
itional regulators and molecules that play critical roles in
melanoma growth and progression, which could serve as
the potential points of intervention for future therapies.
Given the essential nature of YY1 function in different
human carcinomas, we decided to investigate the role
for YY1 in human melanoma. In this study, we perform
RT-qPCR analysis to detect the YY1 mRNA level in both
benign nevi and melanoma specimens. Elevated YY1
levels were observed in patients with melanoma, com-
pared with the levels detected in age/gender-matched
controls with benign nevi and normal tissue controls.
We further identified YY1-targeted miR-9, which was re-
pressed in melanoma cells, was regulated by YY1 and
elucidated its functional significance in regulating mel-
anoma growth and progression. Additionally, RYBP, aPcG protein physically interacts with YY1, was identified
as a novel target of miR-9. We also showed that YY1
could affect RYBP level in melanoma cells, thus forming
a YY1 ~miR-9 ~ RYBP regulatory axis. Collectively, our
results may identify YY1 as a novel regulator of melan-
oma that modulates the miR-9 ~ RYBP axis to promote
melanoma tumorigenesis.
Materials and methods
Human melanoma and benign nevi tissues
Paraffin-embedded pathological samples were obtained
from patients who underwent surgery at Cancer Hospital
of Chinese Academy of Medical Sciences from 2008 to
2014. All specimens were re-evaluated by an expert path-
ologist. Tissues were obtained according to local ethical
guidelines and approved by the local ethics committee.
Skin tissues from 12 patients with melanocytic nevus
(matched by gender and age) were collected as controls.
All samples were snap-frozen in liquid nitrogen, then
stored at −80 °C for further use.
Cell cultures and cell transfection
The melanoma cells lines used in this study were pur-
chased from the Cell Resource Center of IBMS, CAMS.
WM852, WM1791C and WM8 were grown in RPMI
media supplemented with 10 % FBS and penicillin/
streptomycin. FO-1, WM983A, WM793, Daju and
WM209 were grown in MCDB135 media supplemented
with 2 % FBS, insulin, CaCl2, and penicillin/strepto-
mycin. All cells were cultured in a 5 % CO2 humidified
incubator. The melanoma cell lines WM1791C and
WM209 were transfected with miRNA mimic, negative
mimic control, si-YY1, siRNA control (Scramble; Gene-
Pharma; Shanghai, China) at a final concentration of
25 nmol/L using DharmaFECT 1 (Dharmacon; USA) in
accordance with the manufacturer’s instructions.
RNA extraction and quantitative real-time PCR analysis
(RT-qPCR)
The RNeasy FFPE Kit (Qiagen, CA, USA) was used to
purify total RNA from the paraffin-embedded melanoma
tissues as the manufacturer’s instructions. Total RNA
was extracted from the cells and benign nevi tissues
using Trizol reagent (Invitrogen, CA, USA), according to
the manufacturer’s instructions. RT-qPCR assay was
conducted to detect the level of YY1 mRNA and miR-9.
Briefly, cDNA was synthesised by M-MLV reverse tran-
scriptase (Invitrogen) from 5 ug of total RNA. Stem-poop
RT primer was used for the reverse transcription of miR-
9. RT-qPCR was performed on the Bio-rad CFX96 real-
time PCR System (Bio-rad, Foster City, CA, USA) using
KAPA PROBE FAST qPCR Kits (Kapa Biosystems, MA,
USA) with the following cycling conditions: 95 °C for
10 min (initial denature); then 40 cycles of 95 °C for 15 s,
Zhao et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:66 Page 3 of 1160 °C for 60 s. The cycle passing threshold (Ct) was re-
corded for each candidate miRNAs, and miR-9 quantifica-
tion data were normalized to U6, YY1 quantification data
were normalized to GAPDH.
Cell proliferation assay
Cells were incubated in 10 % CCK-8 (DOJINDO, Japan)
diluted in normal culture medium at 37 °C until visual
color conversion occurred. Proliferation rates were de-
termined at 0, 12, 24, 48, 72, 96 h after transfection. The
absorbance of each well was measured with a microplate
reader set at 450nM and 630nM. All experiments were
performed in quadruplicate.
Cell cycle analysis
WM1791C and WM209 were removed with PBS/EDTA
and/or trypsin solution, and centrifuged at 1200 rpm at
4 °C for 5 min. Decant the supernatant and gently re-
suspend the cells in PBS. Count cells by hemocytometer
and wash one time by putting 1X106 cells per tube, add-
ing 1 ml of PBS and centrifuging at 1200 rpm at 4 °C.
Re-suspend pelleted cells in 0.3 ml of PBS buffer and
add 0.7 ml cold ethanol (70 %) dropwise to tube to fix the
cells. Leave on ice for 1 h (or up to a few days at 4 °C),
and centrifuge cells as above, wash 1 time with cold PBS
and re-centrifuge. Add 10 μl of 1 mg/ml PI solution (the
final concentration being 10 μg/ml) and 5 μl of 10 mg/ml
Rnase A (the final concentration being 0.2 mg/ml). Keep
in the dark and at 4 °C until analysis. Analyze on FACS by
reading on cytometer at 488 nm.
Cell migration and invasion assays
WM1791C and WM209 cells were grown to confluence
on 12-well plastic dishes and treated with miRNA
mimics or siRNAs. Then 24 h after transfection, linear
scratch wounds (in triplicate) were created on the con-
fluent cell monolayers using a 200 μL pipette tip. To re-
move cells from the cell cycle prior to wounding, cells
were maintained in serum-free medium. To visualize mi-
grated cells and wound healing, images were taken at 0,
12, 24, 48 h. A total of ten areas were selected randomly
from each well and the cells in three wells of each group
were quantified.
For the invasion assays, after 24 h transfection, 1 × 105
WM1791C cells in serum-free media were seeded onto the
transwell migration chambers (8 μm pore size; Millipore,
Switzerland) which coated with the upper chamber of an
insert coated with Matrigel (Sigma-Aldrich, USA). Media
containing 20 % FBS were added to the lower chamber.
After 24 h, the noninvading cells were removed with cotton
wool, Invasive cells located on the lower surface of the
chamber were stained with May-Grunwald-Giemsa stain
(Sigma-Aldrich, USA) and counted using a microscope(Olympus, Tokyo, Japan). Experiments were independently
repeated three times.
Immunoblotting
Immunoblotting analysis was carried out using stand-
ard methods. Proteins were separated by 10 % SDS-
PAGE, and transferred onto PVDF membranes (Millipore
Corporation, Billerica MA, USA). Membranes were
blocked overnight with 5 % non-fat dried milk for 2 h and
incubated with anti-YY1 antibody (Bioworld) at 1:2000 di-
lution; anti-RYBP (Abcam) antibody at 1:1000 dilution,
anti-GAPDH antibody (Proteintech) at 1:50,000 dilution
overnight at 4 °C. After washing with TBST (10 mM Tris,
pH 8.0, 150 mM NaCl, and 0.1 % Tween20), the mem-
branes were incubated for 2 h at room temperature with
goat anti-rabbit antibody (Zsgb-bio, Beijing, China) at
1:20000.
Statistical analyses
The t-test and a non-parametric test were undertaken to
analyze the data. A two-sided P-value of less than 0.05
was considered statistically significant. All statistical
computations were performed using SPSS (SPSS Inc.,
Chicago, IL, USA).
Results
YY1 is frequently upregulated in melanoma tissues and
cell lines
Given the fact that, elevated expression or nuclear en-
richment of YAP has been observed in multiple types of
human cancers, we first assessed the expression level of
YY1 mRNA in 14 benign nevi and 24 melanoma speci-
mens, including 15 metastatic melanoma (Fig. 1a) by
RT-qPCR analysis. Normal skin tissues were used as
control. As shown in Fig. 1a, a significantly increased
level of YY1 was seen in patients with melanoma (pri-
mary and metastatic melanomas), compared with the
levels detected in age/gender-matched controls with be-
nign nevi (p < 0.01) and normal tissue controls (p <
0.001). Additionally, the YY1 level was observed to be
higher, within tumor cells, in metastatic melanomas than
in primary melanoma (p < 0.001) (Fig. 1b).
Melanoma patients were then grouped by clinical can-
cer stages. There were still positive correlations between
YY1 expression and different tumor stages (p < 0.01, Stage
I-II vs. Normal; p < 0.01, Stage III vs. Stage I-II; p < 0.001
Stage IV vs. Stage III) (Fig. 1c). However, no correlation
was observed between YAP1 expression and age, gender,
localization or tumor size (data not shown). We next ex-
tended our test to eight human melanoma cell lines.
Levels of YY1 transcripts were highly variable across the
panel. Noticeably, expression of YY1 was relatively higher
in four melanoma cell lines without BRAF mutation
(WM852, WM1791C, WM8 and WM209) compared with
Fig. 1 The expression analysis of YY1 in normal skin tissues, benign nevi and melanoma tissues. (a) Relative YY1 mRNA expression levels in
normal skin tissues, benign nevi and melanoma tissues; (b) The Statistical analysis of the association between YY1 level and metastasis state
(primary and metastasis); (c) The Statistical analysis of the association between YY1 level and tumor stage (I, II, III and IV); (d) The relative level of
YY1 mRNA in melanoma cell lines (WM852, WM1791C, WM8, WM209, FO-1, WM983A, WM793 and Daju) relative to 4 normal tissue controls; (e)
Immunoblot of endogenous YAP1 protein level in 3 melanoma tissues, GC cell lines (WM852, WM1791C, WM8 and WM209) relative to 4 normal
tissue controls; An unrelated protein GAPDH was used as the control. For the quantitative results, the data are presented as the mean ± SEM, and
the error bars represent the standard deviation obtained from three independent experiments. *, p < 0.05; **, p < 0.01
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these cell lines showed a notable overexpression of YY1
protein compared to normal clusters with a BRAFV600E
mutation (Fig. 1e). The up-regulation of YY1 protein in
melanoma tissues was also validated in selected samples
(Fig. 1e). Taken together, these results suggest that YY1
might play a regulatory role in melanoma cell growth and
migration, especially for the melanomas that do not har-
bor a BRAFV600E mutation.
Knockdown of YY1 inhibits melanoma cell proliferation
and migration
Because the YY1 was found to be expressed at higher
levels in melanoma cell lines WM852, WM1791C, WM8
and WM209, we chose WM1791C and WM209 to per-
form further assays to test whether YY1 was functionally
involved in malignant melanoma tumorigenesis. siRNAs
specific to YY1 were transfected into the WM1791C and
WM209 cells and the level of YY1 was subsequently
confirmed by RT-qPCR analysis (Fig. 2a). siRNA trans-
fected cells exhibited significantly decreased proliferation
compared with control siRNA transfected WM1791C
and WM209 cells (Fig. 2b). Accordingly, the percentage
of S phase cells was also reduced by ~20 % and ~18 %in si-YY1 transfected WM1791C and WM209 cells re-
spectively (Fig. 2c). Taken together, these results indi-
cated that inhibition of YY1 can efficiently inhibited
tumor cell proliferation and cell cycle in vitro, suggesting
its oncogenic role in modulating tumorigenicity of mel-
anoma cells.
The rapid invasion and metastasis of tumor cells are
responsible for poor prognosis and the major cause of
death in melanoma patients. Based on above statistic re-
sults that YY1 expression displayed close association
with metastasis and malignant degree of tumor, we pro-
posed that it might play an extremely important role in
melanoma cell migration and invasion. To test our hy-
pothesis, cell migration and invasion assays were per-
formed in WM1791C and WM209 cells transfected with
either si-YY1 or siRNA controls (Fig. 2a). Therefore, the
inhibition of endogenous YY1 resulted in a significant re-
duction of cell migration during the closing of an artificial
wound created over a confluent monolayer (Fig. 2d).
Moreover, these cells were maintained in serum-free
medium during the course of wound healing to ensure
that any augmented migratory behavior could not be af-
fected by altered cell proliferation. In addition, reduced ex-
pression of YY1 dramatically inhibited the normally
Fig. 2 Knockdown of YY1 in melanoma cells inhibits cell proliferation, migration and invasion. (a) YY1 level were detected in WM1791C and
WM209 cells after treatment with siRNAs specific to YY1 (25 nM) or siRNA control (25 nM) by RT-qPCR; (b) Cell proliferation assay of WM1791C
and WM209 cells after treatment with si-YY1 or si-control by using CCK-8; (c) Cell cycle analysis by propidium iodide (PI) staining of WM1791C
and WM209 cells after treatment with si-YY1 or si-control; (d) Wound healing assays of WM1791C (the left panel) and WM209 (the right panel)
cells after treatment with si-YY1 or si-control, The relative ratio of wound closure per field was shown in the below; (e) Transwell analysis of
WM1791C cells after treatment with si-YY1 or si-control, The relative ratio of invasive cells per field was shown below. For the quantitative results,
the data are presented as the mean ± SEM, and the error bars represent the standard deviation obtained from three independent experiments. *,
p < 0.05; **, p < 0.01
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the transwell invasion assay (Fig. 2e). These results were
consistent with the above findings that the YY1 could pro-
mote tumor cells growth as well as their progression to-
wards more malignant degree.YY1 resided on the upstream of miR-9 loci and inhibited
its expression
YY1 is a ubiquitously expressed transcription factor, and
the YY1-miRNA axis, as NF-kB- YY1-miR-29 signaling
axis in rhabdomyosarcoma [32, 33] and YY1-miR-1-Pax
Zhao et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:66 Page 6 of 117 axis in skeletal myogenesis [34], has been identified in
different cellular processes. Considering the prevalence
of YY1 binding sites in the genome, we speculate that
many other miRNAs could come under regulation by
YY1, forming numerous functional regulatory circuitries.
Bioinformatics prediction revealed several putative YY1Fig. 3 YY1 inhibites miR-9 expression in melanoma cells. (a) A representati
and miR-9-3 loci. Fragment 1 and 2 represents the amplified fragments in
on three miR-9 loci in WM1791C cells; (c) Q-PCR analysis of YY1 mRNA and m
(d) Relative miR-9 expression levels in normal skin tissues, benign nevi and me
miR-9 level and metastasis state (primary and metastasis); (f) The Statistical an
IV); (g) The relative level of miR-9 in melanoma cell lines (WM852, WM1791C, W
tissue controls. For the quantitative results, the data are presented as the mea
from three independent experiments. *, p < 0.05; **, p < 0.01binding sites scattered within ~1 kb upstream of the
three miR-9 genomic loci (5 sites for miR-9-1 locus, 3
sites for miR-9-2 locus, 6 sites for miR-9-3 locus; Fig. 3a).
The binding of YY1 on these putative sites was exam-
ined by ChIP-q-PCR analysis and confirmed YY1 occu-
pancy on the upstream of miR-9-1 locus and miR-9-3on of YY1 motifs scattered throughout the human miR-9-1, miR-9-2
subsequent ChIP-q-PCR analysis. (b) ChIP-q-PCR analysis of the YY1 hits
iR-9 level in WM1791C cells treated with si-YY1 or si-control for 48 h;
lanoma tissues; (e) The Statistical analysis of the association between
alysis of the association between miR-9 level and tumor stage (I, II, III and
M8, WM209, FO-1, WM983A, WM793 and Daju) relative to 4 normal
n ± SEM, and the error bars represent the standard deviation obtained
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Furthermore, to determine whether YY1 regulated the ex-
pression of miR-9, q-PCR was performed in WM1791C cells
upon si-YY1 treatment (Fig. 3c). As expected, inhibition ofFig. 4 Overepression of miR-9 inhibits melanoma cell proliferation, migratio
WM209 cells after treatment with miR-9 mimic (25 nM) or mimic control (2
WM209 cells after treatment with miR-9 mimic or mimic control by using C
WM1791C and WM209 cells after treatment with miR-9 mimic or mimic co
WM209 (the right panel) cells after treatment with miR-9 mimic or mimic c
below; (e) Transwell analysis of WM1791C cells after treatment with miR-9
shown below. For the quantitative results, the data are presented as the mean
from three independent experiments. *, p < 0.05; **, p < 0.01YY1 increased miR-9 by ~2-fold, suggesting a transcriptional
inhibition by YY1 on miR-9 in melanoma cells.
Given the regulatory roles of YY1 on miR-9 expres-
sion, we continued to detect whether the expression ofn and invasion. (a) miR-9 level were detected in WM1791C and
5 nM) by RT-qPCR; (b) Cell proliferation assay of WM1791C and
CK-8; (c) Cell cycle analysis by propidium iodide (PI) staining of
ntrol; (d) Wound healing assays of WM1791C (the left panel) and
ontrol, The relative ratio of wound closure per field was shown in the
mimic or mimic control, The relative ratio of invasive cells per field was
± SEM, and the error bars represent the standard deviation obtained
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As shown in Fig. 3d, downregulation of miR-9 was seen
in patients with melanoma compared to the normal tis-
sue controls (p < 0.01). However, there was no statistical
significance of miR-9 level between melanoma speci-
mens and benign nevi. We further found that decreased
miR-9 was associated with metastasis state (p < 0.01, pri-
mary vs. metastasis) (Fig. 3e) and different tumor stages
stage (p < 0.05 Stage IV vs. Stage III) (Fig. 3f ).
Overexpression of miR-9 in melanoma cells inhibits cell
proliferation, migration and invasion
To test the potential roles of miR-9 in melanoma car-
cinogenesis, we first detected the relative expression
level of miR-9 in different melanoma cell lines and the
results showed that miR-9 was significantly down-
regulated in WM852, WM1791C, WM8 and WM209
(Fig. 3g). Of them, WM1791C and WM209 were se-
lected to analyze the role of miR-9. RT-q-PCR was first
used to measure the level of miR-9 after transfection
and showed that the level of miR-9 was ~200-fold higher
in miR-9 mimic-transfected WM1791C and WM209
cells (Fig. 4a). Accordingly, the CCK-8 proliferation assay
in the same cells indicated that cell growth was sup-
pressed after transfection with miR-9 mimic (Fig. 4b).
Additionally, the cell cycle progression was also inhib-
ited upon miR-9 mimic treatment (Fig. 4c). Furthermore,Fig. 5 RYBP is repressed by miR-9 in melanoma cells. (a) A computer pred
of human RYBP mRNAs for miR-9; (b) Relative luciferase activity of the indicate
obtained from three independent experiments; (c) Immunoblot analysis o
or miR-9 mimics; An unrelated protein GAPDH was used as the control. (d) Im
with si-YY1 or si-control; An unrelated protein GAPDH was used as the contro
and miR-9 inhibitor or inhibitor control. An unrelated protein GAPDH was use
the mean ± SEM, and the error bars represent the standard deviation obtainedthe wound healing assay showed that cell migration was
inhibited in miR-9 mimic-transfected WM1791C and
WM209 cells compare to the mimic control-transfected
ones (Fig. 4d), suggesting the inhibitory effects of miR-9
on tumor cell migration. To detect whether miR-33b
possesses the ability to inhibit cell invasion, transwell in-
vasion assay was performed. As expected, there was sig-
nificant reduction in cell invasiveness after miR-9 mimic
transfection in WM1791C cell lines (Fig. 4e). Taken to-
gether, these results indicated the tumor suppressive
roles of miR-9 in GC cells, which was opposite to its
negative regulator YY1.
YY1 ~miR-9 ~ RYBP axis in melanoma cells
Biological role of miR-9 in melanoma cells promoted us
to study its mechanism in carcinogenesis. To this aim,
we started to search for the mRNA targets of miR-9.
After alignment, we found a putative binding site of
miR-9 in the 3′UTR of RYBP mRNA (Fig. 5a). To valid-
ate whether miR-9 targets RYBP, we first cloned the
wild-type (RYBP_WT) or miR-9-binding site-mutant
(RYBP_MUT) RYBP 3' UTRs (Fig. 5a) into a pMIR-
reporter plasmid and co-transfected these constructs
into 293 T cells with an miR-9 mimic or a mimic-control,
respectively. Reporter assays in 293 T cells revealed that
miR-9 significantly reduced the luciferase activities of
wild-type RYBP reporters compared to the controliction of the conserved and mutated binding sites within the 3' UTR
d RYBP reporter constructs. Error bars represent the standard deviation
f RYBP in WM1791C and WM209 cells transfected with mimic control
munoblot analysis of RYBP in WM1791C and WM209 cells transfected
l. (e) Immunoblot analysis of RYBP in WM1791C transfected with si-YY1,
d as the control. For the quantitative results, the data are presented as
from three independent experiments. *, p < 0.05; **, p < 0.01
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reporters were not repressed by miR-9, indicating that the
repression was dependent on miRNA binding (Fig. 5b).
Moreover, immunoblotting assay was carried out in
WM1791C and WM209 cells and showed that RYBP pro-
tein was about 2-fold lower in cells transfected with miR-9
mimics (Fig. 5c).
Based on above findings that YY1 negatively regulated
miR-9 and miR-9 repressed RYBP expression, we specu-
lated that the modification of YY1 level would ultimately
changed RYBP expression. To test this hypothesis, we
used si-YY1 to inhibit the endogenous YY1 activity in
melanoma cells. As expected, YY1 knockdown resulted
in an obvious decrease of RYBP level in both WM1791C
and WM209 cells (Fig. 5d). Furthermore, to test whether
the regulation of YY1 on RYBP expression is mediated
by miR-9 in melanoma cells, we performed a “rescue”Fig. 6 Knock-down of RYBP inhibits melanoma cell proliferation, migration
treatment with si-RYBP (25 nM) or si-control (25 nM) by RT-qPCR; (b) Cell p
si-control by using CCK-8; (c) Cell cycle analysis by propidium iodide (PI) st
(d) Wound healing assays of WM1791C cells after treatment with si-RYBP o
the right; (e) Transwell analysis of WM1791C cells after treatment with si-RY
below. For the quantitative results, the data are presented as the mean ± S
three independent experiments. *, p < 0.05; **, p < 0.01assay with the combination of si-YY1 and miR-9 inhibi-
tor in WM1791C cells. As expected, si-YY1 treatment
led to a 2-fold decrease in RYBP protein levels compared
to the control (Fig. 5e, panel 1 and 2). Furthermore, the
addition of miR-9 inhibitor following si-YY1 treatment
resulted in the increase of RYBP protein compared to in-
hibitor controls (Fig. 5e, panel 2 and 3), which suggest-
ing that the regulation of RYBP by YY is indeed
mediated by miR-9.
The above findings made us to further investigate the
potential involvement of RYBP in melanoma carcinogen-
esis. Firstly, the CCK-8 proliferation assay in the
WM1791C cells showed that cell growth was a little sup-
pressed after knock-down of RYBP by siRNAs (Fig. 6a, b).
Accordingly, the cell cycle progression was also inhibited
in RYBP silencing WM1791C cells. (Fig. 6c). Furthermore,
the wound healing and transwell indicated that celland invasion. (a) RYBP level was detected in WM1791C cells after
roliferation assay of WM1791C cells after treatment with si-RYBP or
aining of WM1791C cells after treatment with si-RYBP or si-control l;
r si-control, The relative ratio of wound closure per field was shown in
BP or si-control The relative ratio of invasive cells per field was shown
EM, and the error bars represent the standard deviation obtained from
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RYBP-transfected WM1791C cells compare to the si-
control-transfected ones (Fig. 6d, e). Taken together, these
results indicated that RYBP could regulate cell prolifera-
tion, migration and invasion of melanoma cells, further
confirming the YY1 ~miR-9 ~ RYBP axis in melanoma
cells.
Discussion
YY1 is a transcription factor with complex biological
functions, including apoptosis, tumorigenesis, develop-
ment and differentiation. Overexpression of YY1 in
tumor tissues exerts different clinical behavior in differ-
ent tumor types. Moreover, in many human cancer
types, YY1 expression levels were found to be signifi-
cantly elevated in the metastatic tumor compared to its
primary counterpart, supporting the potential role of
YY1 in cancer development [18, 20]. However, its in-
volvement in melanoma tumorigenesis has not been well
defined. In that regard, it would be interesting to test the
biological and mechanistic significance of YY1 in melan-
oma. In general, our observations corroborated that YY1
was an oncogenic regulator for human melanoma.
Therefore, its regulation in cancer along with the devel-
opment of new therapeutic targets of YY1 may represent
promising tools against melanoma therapy.
In the current study, RYBP, a PcG member was discov-
ered to be a direct target of miR-9 in melanoma cells.
PcG proteins are crucial for epigenetic inheritance of cell
identity and are functionally conserved from Drosophila
to human [35]. PcG proteins are also perturbed in a
range of cancers, suggesting that they are critical for
maintenance of normal cell identity [36–38]. In mam-
mals, the PcG proteins are generally found in one of two
protein complexes, the polycomb repressive complexes 1
or 2 (PRC1 or PRC2). Molecular characterization of the
PRC complexes has revealed the combined activities of
PRC1 and PRC2 in target gene recognization. Specific-
ally, H3K27me3 placed by PRC2 is recognized by PRC1
complexes that contain chromobox (CBX) proteins,
which represents a canonical model for PRC recruit-
ment. Alternatively, the recent demonstration that vari-
ant PRC1 complexes (containing RYBP/YAF2 instead of
CBX) bind to many target sites, albeit at lower levels,
can be achieved in the absence of PRC2. Previous studies
have identified RYBP as a transcription silencer in em-
bryogenesis [39], skeletal myogenesis [34] and central
nervous system development [40]. Our current study
demonstrated a potential role of RYBP in melanoma
tumorigenesis. Furthermore, RYBP and YY1 were found
to co-occupy several target promoters/enhancers of YY1
to silence their expression, thereby a YY1 ~miR-9 ~
RYBP feedback regulatory loop might be existed in mel-
anoma cells.Conclusions
In line with the other studies, our results suggested YY1
as a transcriptional repressor of miR-9 and a promoter
of melanoma growth and progression by modulating the
miR-9 ~ RYBP axis.
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